ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. regarding alleged violations of federal securities laws related to misleading statements about the efficacy of its drug, efzofitimod, leading to significant financial losses for investors [3][6]. Group 1: Legal Action and Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in aTyr Pharma to contact them for discussing legal options, particularly for those who purchased securities between January 16, 2025, and September 12, 2025 [2][3]. - A federal securities class action has been filed against aTyr Pharma, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [3][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against aTyr Pharma - The complaint alleges that aTyr Pharma and its executives made false and misleading statements regarding the drug efzofitimod, particularly about its ability to allow patients to taper off steroid usage completely [6]. - The EFZO-FIT study results indicated that efzofitimod did not show a significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from $6.03 on September 12 to $1.01 on September 15 [7].